Alzheimers Disease Research Foundation
- Assets
- $30.2m
- Revenue
- $40.7m
- Investments
- $0.0
- Employees
- 33
- Location
- Wellesley Hills, MA
- Founding
- 10/2006
- Data as of
- 12/2022
- EIN
- 52-2396428
Organization Overview
Alzheimers Disease Research Foundation, operating under the name Cure Alzheimer's Fund, is located in Wellesley Hills, MA. The organization was established in 2006. According to its NTEE Classification (H83) the organization is classified as: Alzheimers Disease Research, under the broad grouping of Medical Research and related organizations. As of 12/2022, Cure Alzheimer's Fund employed 33 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Cure Alzheimer's Fund is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Cure Alzheimer's Fund generated $40.7m in total revenue. This organization has experienced exceptional growth, as over the past 8 years, it has increased revenue by an average of 17.4% each year . All expenses for the organization totaled $30.6m during the year ending 12/2022. While expenses have increased by 11.3% per year over the past 8 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Cure Alzheimer's Fund has awarded 560 individual grants totaling $124,020,937. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE.
Describe the Organization's Program Activity:
Part 3 - Line 4a
IN 2022, CURE ALZHEIMER'S FUND SUPPORTED 100 RESEARCH PROJECTS AT 59 LEADING RESEARCH INSTITUTIONS, FOR RESEARCH OUTPUT OF MORE THAN $24.4 MILLION. MANY PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF THE BRAIN'S INNATE IMMUNE SYSTEM AND THE CONTROL OF THE ENTRY AND EXIT OF MATERIALS FOR HEALTHY BRAIN FUNCTION. ADDITIONAL EXPENSES INCLUDE HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES.
CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Timothy Armour President & CEO | OfficerTrustee | 40 | $242,641 |
Laurel Lyle Secretary & VP Board Relations And Development | OfficerTrustee | 30 | $105,067 |
Henry Mccance Co-Chairman | OfficerTrustee | 5 | $0 |
Jeffrey Morby Co-Chairman | OfficerTrustee | 20 | $0 |
Phyllis Rappaport Treasurer | OfficerTrustee | 2 | $0 |
Robert Greenhill Director | Trustee | 2 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Gryphon Consulting Inc Financial & Mgt Consultant | 12/30/22 | $175,283 |
Proper Villains Inc Creative And Production Services | 12/30/22 | $297,563 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $313,024 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $32,041,631 |
| Noncash contributions included in lines 1a–1f | $5,919,199 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $32,354,655 |
| Total Program Service Revenue | $0 |
| Investment income | $93,408 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $8,266,319 |
| Net Income from Fundraising Events | -$6,137 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $40,708,245 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $19,201,841 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $4,229,886 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $1,127,225 |
| Compensation of current officers, directors, key employees. | $88,620 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $2,381,842 |
| Pension plan accruals and contributions | $65,929 |
| Other employee benefits | $130,430 |
| Payroll taxes | $245,877 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $15,537 |
| Fees for services: Accounting | $149,145 |
| Fees for services: Lobbying | $75,000 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $30,344 |
| Fees for services: Other | $545,564 |
| Advertising and promotion | $777,562 |
| Office expenses | $245,287 |
| Information technology | $89,313 |
| Royalties | $0 |
| Occupancy | $196,349 |
| Travel | $108,919 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $250,410 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $3,907 |
| Insurance | $23,125 |
| All other expenses | $0 |
| Total functional expenses | $30,613,014 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $2,778,505 |
| Savings and temporary cash investments | $7,254,987 |
| Pledges and grants receivable | $1,877,735 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $218,532 |
| Net Land, buildings, and equipment | $3,042 |
| Investments—publicly traded securities | $17,733,326 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $326,657 |
| Total assets | $30,192,784 |
| Accounts payable and accrued expenses | $129,949 |
| Grants payable | $763,585 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $840,640 |
| Total liabilities | $1,734,174 |
| Net assets without donor restrictions | $26,297,281 |
| Net assets with donor restrictions | $2,161,329 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $30,192,784 |
Grants Awarded
Over the last fiscal year, Alzheimers Disease Research Foundation has awarded $19,108,307 in support to 85 organizations.
| Grant Recipient | Amount |
|---|---|
UNIVERSITY OF CONNECTICUT PURPOSE: AD PATHOPHYSIOLOGY ALTERS THE LEVEL OF ELECTRICAL AND CHEMICAL SYNAPSE COUPLING IN THE NETWORK OF GABAERGIC PV+ INTERNEURONS EARLY IN DISEASE COURSE | $230,000 |
WASHINGTON UNIVERSITY PURPOSE: APOE: ASSESSING THE ADDED DIAGNOSTIC VALUE OF PERIPHERAL APOE PROTEIN LEVELS IN CURRENT BLOOD-BASED BIOMARKER ASSAYS FOR CNS AMYLOIDOSIS | $252,077 |
YALE PURPOSE: BEE: CNS FLUID HOMEOSTASIS AND WASTE CLEARANCE IN ALZHEIMERS DISEASE CHARACTERIZED BY MRI | $204,238 |
MASSACHUSETTS GENERAL HOSPITAL PURPOSE: EFFECTS OF DE-PALMITOYLATION AND ACAT INHIBITION ON AXONAL AB GENERATION VIA MAM-ASSOCIATED PALAPP | $172,500 |
DUKE PURPOSE: CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMERS PATHOLOGY IN MICE | $194,253 |
MOUNT SINAI PURPOSE: ESTABLISHING THE MOLECULAR AND CELLULAR MECHANISMS AND BIOMARKERS OF APOE4-MEDIATED SUSCEPTIBILITY TO TAU-RELATED COGNITIVE IMPAIRMENTS | $172,500 |